David J. Andorsky, MD

David J. Andorsky, MD, is a medical oncologist and hematologist at Rocky Mountain Cancer Centers; as well as the associate chair of US Oncology Hematology Research.

Articles by David J. Andorsky, MD

Dr Andorsky on Molecular Responses With Second-Line Asciminib in CP-CML

ByDavid J. Andorsky, MD

April 10th 2025

David J. Andorsky, MD, discusses molecular responses achieved with asciminib dose escalation in patients with CP-CML who had received 1 prior TKI.

Dr Andorsky on Real-World Treatment Patterns With BTK Inhibitors in CLL/SLL

ByDavid J. Andorsky, MD

December 12th 2023

David J. Andorsky, MD, discusses recently observed patterns of care with BTK inhibitors in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in the community setting in the United States, and how social determinants of health may have affected these outcomes.

Dr. Andorsky on the Results of a Subgroup Analysis of the MAGNIFY Trial in NHL

ByDavid J. Andorsky, MD

January 5th 2021

David J. Andorsky, MD, discusses the results of a subgroup analysis of the phase 3b MAGNIFY trial in relapsed/refractory non-Hodgkin lymphoma.

Dr. Andorsky on Next Steps Following MAGNIFY Trial in Follicular Lymphoma

ByDavid J. Andorsky, MD

August 24th 2017

David J. Andorsky, MD, medical oncology/hematology, Rocky Mountain Cancer Centers, discusses the next steps of the phase IIIb randomized MAGNIFY study of lenalidomide (Revlimid) plus rituximab (Rituxan) followed by maintenance therapy in relapsed/refractory non-Hodgkin lymphoma, focusing on a cohort of patients with follicular lymphoma.

Dr. Andorsky on the MAGNIFY Trial in Follicular Lymphoma

ByDavid J. Andorsky, MD

August 3rd 2017

David J. Andorsky, MD, medical oncology/hematology, Rocky Mountain Cancer Centers, discusses the phase IIIb randomized MAGNIFY study of lenalidomide (Revlimid) plus rituximab (Rituxan) followed by maintenance therapy in relapsed/refractory non-Hodgkin lymphoma, focusing on a cohort of patients with follicular lymphoma.